Proposals & Solutions

INITIATE: Medical Device Trials
American medical device company:
 
“We are 3 months in to a two-year project with our Kazakhstani partners. Things are not going well. We can’t get through to our partners. We are experiencing communication problems, organizational confusion and project management is in chaos. Should we pull the plug on this project, or is there a way to salvage it and turn it into a winning proposition?”

&

EBMrc:
 
This is a common experience during first entry into Kazakhstan. We tell our clients that miscommunication is not likely to happen, it is guaranteed to happen. But there are other advantages to doing a clinical research project in Kazakhstan that can counterbalance these challenges. Choosing the proper response can make or break the project. We can help interpret the situation, put the right local experts on the project, and advise next steps.
LAUNCH: Phase III Pharmaceutical Trials
Top 5 Pharmaceutical company based in Germany:
 
“We want to run a phase III study in Kazakhstan because of (1) cost attractiveness, (2) no competing studies at sites in Kazakhstan and we also want to build relationships with key opinion leaders. We also heard that regulatory review times are competitive. We want to find sites that have trained physicians and get our study up and going within 6 months.”

&

EBMrc:
 
Kazakhstan has all of the advantages mentioned. Many sites have good infrastructure. There are physicians and hospital sites familiar with Good Clinical Practice and international trial standards, but one needs to be selective in choosing appropriate trial sites. We can help navigate regulatory submissions, identify clinician investigators and initiate and monitor phase II, III and IV pharmaceutical studies.


ACCESS: Pharmaceutical Market Access in Kazakhstan
Large pharmaceutical-focused consultancy based in Western Europe:
 
“We want to explore the possibilities of bringing high cost pharmaceutical products for out-of-pocket purchase in Kazakhstan. We need interview data from high level health care leaders, physician leaders, pharmacists and patients. We don’t have staff in Kazakhstan and need a competent consultant to lead and administer this discrete project.”

&

EBMrc:
 
Kazakhstan’s economy is growing at a substantial rate (~4% per annum) and with this growth, a new market for high-cost innovative pharmaceuticals has emerged. In this instance, through our network of contacts, we can identify drug reimbursement processes, key motivating factors and describe the important public/private interface and through key opinion leaders we can gather qualitative and quantitative data on which to base market entry decisions.


MEDICAL WRITING: Building Kazakhstan’s medical publishing capacity through medical writing
Large, Kazakhstan-based medical center:
 
“We have busy physicians that highly motivated to publish in English-language peer-reviewed journals, but some lack the necessary training in research methodology, epidemiology or biostatistics. International journals have high standards for medical writing in English and this represents a barrier for some of our clinician researchers. We need a system for identifying and fostering research with significant potential for manuscript acceptance.”

&

EBMrc:
 
There is increasing impetus in Kazakhstan to publish results of medical research in journals which have reach beyond the borders of the former Soviet Union. Some medical centers in Kazakhstan have developed their research standards to an international calibre. We can partner with such facilities to promote good processes for data collection, analysis and interpretation. Crucially, we can help to overcome the English language barrier through our medical writing services.